Current Weather
The Spy FM

Johnson & Johnson To Pay $2.2 Billion In Marketing Settlement

Filed by KOSU News in Business.
November 4, 2013

Johnson & Johnson became the latest drugmaker to reach a costly agreement with the federal government over charges of improper marketing.

The widely anticipated settlement, unveiled Monday, covers Natrecor, a drug for congestive heart failure, and antipsychotics Risperdal and Invega.

Under the deal with the Justice Department, Johnson & Johnson will pay $2.2 billion to resolve various allegations. Those involving Risperdal accounted for the majority of the money involved.

The company’s Janssen Pharmaceuticals subsidiary also pleaded guilty to a misdemeanor charge related to the promotion of antipsychotic Risperdal for the management of dementia in elderly patients.

While paying up to settle the civil charges, the company continues to dispute them. “The settlement of the civil allegations is not an admission of any liability or wrongdoing, and the Company expressly denies the government’s civil allegations,” Johnson & Johnson said in statement.

“Risperdal was never approved by the [Food and Drug Administration] for the treatment of dementia,” the government’s criminal information notes. Yet about half of Risperdal prescribed a decade ago was for elderly patients suffering from dementia, rather than schizophrenia or bipolar disease, the government documents show. For years, the company deployed sales reps who called on doctors specializing in the care of elderly patients to play up the unapproved use of the drug for dementia.

Besides being unapproved for dementia treatment, the use of Risperdal also carried significant side effects, such as an increased risk for strokes and diabetes, which the company allegedly downplayed. Sales reached a $4.7 billion peak in 2007, when Risperdal was the company’s best-selling drug.

Like professional baseball, the drug industry may need to slap asterisks next to some of its standout accomplishments.

Allegations and admissions about players’ use of performance-enhancing drugs have marred the records compiled by some of baseball’s stars. For the pharmaceutical industry, overactive marketing has juiced sales of drugs that might have languished in the minor leagues without them.

Federal penalties levied against drugmakers for alleged fraud surpassed those for defense contractors, according to a 2010 report.

No. 1 on the settlement list is GlaxoSmithKline, which agreed in 2012 to pay $3 billion and plead guilty to criminal charges related to antidepressants Paxil and Wellbutrin and the diabetes drug Avandia. Back in 2009, Pfizer ponied up $2.3 billion to settle allegations related mainly to the painkiller Bextra in the second biggest settlement to date.

The J&J deal was a long time in the making. The investigations stretch back nearly 10 years. A tentative agreement on the Risperdal charges was reached a while back, as the company has disclosed in its financial statements.

Why so long to get to this point? “This was a complex matter and we cooperated with the government since the separate investigations began over a decade ago,” company spokesman Ernie Knewitz told Shots in an email. “It was always important to get this done right, and now we are looking forward to continuing to deliver innovative treatments to patients.” [Copyright 2013 NPR]

Leave a Reply

10AM to 11PM On Point

On Point

On Point unites distinct and provocative voices with passionate discussion as it confronts the stories that are at the center of what is important in the world today. Leaving no perspective unchallenged, On Point digs past the surface and into the core of a subject, exposing each of its real world implications.

Listen Live Now!

11AM to 12PM The Story

The Story

The Story with Dick Gordon brings the news home through first-person accounts. The live weekday program is passionate, personal, immediate and relevant to listeners, focusing on the news where it changes our lives, causes us to stop and rethink, inspires us.

View the program guide!

12PM to 1PM Fresh Air

Fresh Air

This one-hour program features Terry Gross' in-depth interviews with prominent cultural and entertainment figures, as well as distinguished experts on current affairs and news.

View the program guide!

Upcoming Events in your area (Submit your event today!)

Streaming audio and podcasts

Stream KOSU on your smartphone

Phone Streaming

SmartPhone listening options on this page are intended for many iPhones, Blackberries, etc. with low-cost software applications available to listen to our full-time web streams, both News on KOSU-1 and Classical on KOSU-2.

Learn more about our complete range of streaming services

We're perfecting the patient experience - Stillwater Medical Center